Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat versus darbepoetin alfa for maintenance treatment of anemia in adults on hemodialysis converting from ESA therapy
2019-004851-36Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vadadustat and darbepoetin alfa in anemia of chronic kidney disease (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Jun 2020; status: completed.
02
Drugs
vadadustatdarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2019-004851-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004851-36.